Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Novarel (Ferring): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Novarel (Ferring) - General Information

Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.

 

Pharmacology of Novarel (Ferring)

Novarel (Ferring) is used to treat female infertility, Novarel (Ferring) stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Ovidrel is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.

 

Novarel (Ferring) for patients

 

Novarel (Ferring) Interactions

 

Novarel (Ferring) Contraindications

Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) is contraindicated in women who exhibit:

1. Prior hypersensitivity to hCG preparations or one of their excipients.

2. Primary ovarian failure.

3. Uncontrolled thyroid or adrenal dysfunction.

4. An uncontrolled organic intracranial lesion such as a pituitary tumor.

5. Abnormal uterine bleeding of undetermined origin.

6. Ovarian cyst or enlargement of undetermined origin.

7. Sex hormone dependent tumors of the reproductive tract and accessory organs.

8. Pregnancy.

 

Additional information about Novarel (Ferring)

Novarel (Ferring) Indication: For the treatment of female infertility Mechanism Of Action: Novarel (Ferring) binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Choriogonadotropin alfa Synonyms: Choriogonadotropin beta chain precursor; Chorionic gonadotrophin beta subunit; CG-beta Drug Category: Fertility Agents; Gonadotropins Drug Type: Biotech; Approved Other Brand Names containing Choriogonadotropin alfa: Novarel (Ferring); Ovidrel (Serono SA); Pregnyl (Organon); Profasi (Serono); Absorption: The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%. Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours). Dosage Forms of Novarel (Ferring): Injection, solution Subcutaneous Chemical IUPAC Name: Human chorionic gonadotropin Chemical Formula: C1105H1770N318O336S26 Choriogonadotropin alfa on Wikipedia: https://en.wikipedia.org/wiki/Choriogonadotropin_alfa Organisms Affected: Humans and other mammals